C3 Glomerulopathy

• CLINICAL_TRIALS trial_result · 2026-04-13
  Clinical Trial Update: Study of NM8074 in Adult C3 Glomerulopathy Patients [Phase 1, Phase 2]

  This clinical trial update reports a Phase 1/2 study of NM8074 for adult patients with C3 glomerulopathy, noting that the study is not yet r…

• CLINICAL_TRIALS trial_result · 2026-03-30
  Clinical Trial Update: Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 [Phase 2]

  Omeros' Phase 2 safety study of OMS721 in immunoglobulin A nephropathy, lupus nephritis, membranous nephropathy, and C3 glomerulopathy inclu…

• CLINICAL_TRIALS trial_result · 2025-12-16
  Clinical Trial Update: Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease [Phase 1, Phase 2]

  This document reports the completion of a Phase 1/2 study of ARO-C3 from Arrowhead Pharmaceuticals in adults, including healthy volunteers a…

• CLINICAL_TRIALS trial_result · 2025-08-06
  Clinical Trial Update: Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis [Phase 3]

  Phase 3 trial evaluating pegcetacoplan for C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis has completed with …

• CLINICAL_TRIALS trial_result · 2025-06-19
  Clinical Trial Update: Home Reported Outcomes in C3G Study

  This clinical trial update indicates a study evaluating home-reported outcomes in patients with C3 glomerulopathy is currently recruiting. I…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2025-02-07
  Clinical Trial Update: Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN [Phase 2]

  Phase 2 trial assessing pegcetacoplan for post-transplant recurrence of C3 glomerulopathy and immune complex-mediated MPGN has completed wit…

• CLINICAL_TRIALS trial_result · 2022-10-14
  Clinical Trial Update: Controlled Trial Evaluating Avacopan in C3 Glomerulopathy [Phase 2]

  Amgen completed a controlled Phase 2 trial of avacopan in C3 glomerulopathy. The study results were posted in October 2022.

• CLINICAL_TRIALS trial_result · 2022-08-11
  Clinical Trial Update: A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 [Phase 2]

  Phase 2 proof-of-concept trial for a 12-month treatment in C3 glomerulopathy-related conditions (C3 Glomerulonephritis/IC-MPGN) with ACH-014…

• CLINICAL_TRIALS trial_result · 2022-07-08
  Clinical Trial Update: Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted [Phase 2]

  Phase 2 trial evaluating efficacy and safety of LNP023 in C3 glomerulopathy patients, including transplanted and non-transplanted cohorts, h…

• CLINICAL_TRIALS trial_result · 2021-11-04
  Clinical Trial Update: A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) [Phase 2]

  Phase 2 proof-of-concept trial of danicopan for six months in participants with C3 glomerulopathy has completed with results posted.

• CLINICAL_TRIALS trial_result · 2021-07-13
  Clinical Trial Update: A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN [Phase 2]

  Phase 2 trial assessing danicopan effects on C3 levels in participants with C3 glomerulopathy or IC-MPGN; the study is completed with result…